Miquel Bernardo1, Fernando Rico-Villademoros2,3, Clemente García-Rizo4, Rosa Rojo5, Ricardo Gómez-Huelgas6. 1. Department of Psychiatry, Hospital Clínic, University of Barcelona, Idibaps, Cibersam, Barcelona, Spain. bernardo@clinic.cat. 2. Institute of Neurosciences, University of Granada, Granada, Spain. 3. Cociente S.L., Madrid, Spain. 4. Department of Psychiatry, Hospital Clínic, University of Barcelona, Idibaps, Cibersam, Barcelona, Spain. 5. Faculty of Health Sciences, Alfonso X El Sabio University, Villanueva de la Cañada, Madrid, Spain. 6. Internal Medicine Department, Instituto de Investigación Biomedica de Malaga-IBIMA, Regional University Hospital of Malaga, Malaga, Spain.
Abstract
INTRODUCTION: To assess the risk of occurrence and potential determinants of metabolic disorders in adult patients treated with second-generation antipsychotics (SGAs) under real-world practice conditions. METHODS: MEDLINE, EMBASE, and PsycInfo were searched in July 2019 from database inception. We included population-based, longitudinal, comparative studies that report the results of the outcomes of interest for adult participants, including diabetes, ketoacidosis, hyperosmolar hyperglycemic state, weight gain/obesity, dyslipidemia, hypertension, and metabolic syndrome. Two reviewers independently extracted data on the study design, study quality, and study outcomes. RESULTS: We included 40 studies. Most studies showed that clozapine and olanzapine were associated with an increased likelihood of developing diabetes, while the results for risperidone and quetiapine were mixed. Although less well studied, ziprasidone and aripiprazole appeared to not be associated with the occurrence of diabetes. Information on antipsychotic-induced weight gain/obesity is extremely scarce. Regarding dyslipidemia, aripiprazole was not associated with an increased likelihood of developing dyslipidemia, clozapine was associated with an increased likelihood of developing dyslipidemia, and risperidone, olanzapine, quetiapine, and ziprasidone showed mixed results. Two studies suggested an association between ziprasidone and the occurrence of hypertension. Several studies found that the occurrence of a metabolic disorder acted as a risk factor for the development of other metabolic disorders. We did not find information on brexpiprazole, cariprazine, or lurasidone, and data on any long-acting SGA were lacking. CONCLUSION: Although there are relevant differences among SGAs concerning the risk of metabolic disorders, it appears that none of the SGAs included in our review are fully devoid of these disturbances.
INTRODUCTION: To assess the risk of occurrence and potential determinants of metabolic disorders in adult patients treated with second-generation antipsychotics (SGAs) under real-world practice conditions. METHODS: MEDLINE, EMBASE, and PsycInfo were searched in July 2019 from database inception. We included population-based, longitudinal, comparative studies that report the results of the outcomes of interest for adult participants, including diabetes, ketoacidosis, hyperosmolar hyperglycemic state, weight gain/obesity, dyslipidemia, hypertension, and metabolic syndrome. Two reviewers independently extracted data on the study design, study quality, and study outcomes. RESULTS: We included 40 studies. Most studies showed that clozapine and olanzapine were associated with an increased likelihood of developing diabetes, while the results for risperidone and quetiapine were mixed. Although less well studied, ziprasidone and aripiprazole appeared to not be associated with the occurrence of diabetes. Information on antipsychotic-induced weight gain/obesity is extremely scarce. Regarding dyslipidemia, aripiprazole was not associated with an increased likelihood of developing dyslipidemia, clozapine was associated with an increased likelihood of developing dyslipidemia, and risperidone, olanzapine, quetiapine, and ziprasidone showed mixed results. Two studies suggested an association between ziprasidone and the occurrence of hypertension. Several studies found that the occurrence of a metabolic disorder acted as a risk factor for the development of other metabolic disorders. We did not find information on brexpiprazole, cariprazine, or lurasidone, and data on any long-acting SGA were lacking. CONCLUSION: Although there are relevant differences among SGAs concerning the risk of metabolic disorders, it appears that none of the SGAs included in our review are fully devoid of these disturbances.
Authors: Frank D Gianfrancesco; Amy L Grogg; Ramy A Mahmoud; Ruey-hua Wang; Henry A Nasrallah Journal: J Clin Psychiatry Date: 2002-10 Impact factor: 4.384
Authors: S Mas; P Gassó; N Rodríguez; B Cabrera; G Mezquida; A Lobo; A González-Pinto; M Parellada; I Corripio; E Vieta; J Castro-Fornieles; J Bobes; J Usall; J Saiz-Ruiz; F Contreras; E Parellada; M Bernardo Journal: Acta Psychiatr Scand Date: 2019-12-05 Impact factor: 6.392
Authors: Davy Vancampfort; Brendon Stubbs; Alex J Mitchell; Marc De Hert; Martien Wampers; Philip B Ward; Simon Rosenbaum; Christoph U Correll Journal: World Psychiatry Date: 2015-10 Impact factor: 49.548
Authors: D Vancampfort; C U Correll; M Wampers; P Sienaert; A J Mitchell; A De Herdt; M Probst; T W Scheewe; M De Hert Journal: Psychol Med Date: 2013-11-21 Impact factor: 7.723
Authors: Davy Vancampfort; Kristof Vansteelandt; Christoph U Correll; Alex J Mitchell; Amber De Herdt; Pascal Sienaert; Michel Probst; Marc De Hert Journal: Am J Psychiatry Date: 2013-03 Impact factor: 18.112
Authors: Toby Pillinger; Robert A McCutcheon; Luke Vano; Yuya Mizuno; Atheeshaan Arumuham; Guy Hindley; Katherine Beck; Sridhar Natesan; Orestis Efthimiou; Andrea Cipriani; Oliver D Howes Journal: Lancet Psychiatry Date: 2019-12-17 Impact factor: 77.056
Authors: C U Correll; Ofer Agid; Benedicto Crespo-Facorro; Andrea de Bartolomeis; Andrea Fagiolini; Niko Seppälä; Oliver D Howes Journal: CNS Drugs Date: 2022-06-27 Impact factor: 6.497